Prevalence, Incidence and Risk Signature of Chronic Kidney Disease in Sub-Saharan Africa

NCT05881447 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 1200

Last updated 2026-04-29

No results posted yet for this study

Summary

Chronic kidney disease (CKD) is associated with increased cardiovascular morbidity and mortality. The prevalence of CKD is increasing worldwide and is assumed to also dramatically increase in Sub-Saharan Africa (SSA). Key shortcomings of available data on CKD in SSA are as follows: (i) Available data are based on single measurements and, therefore, cannot distinguish between harmless transient deterioration in kidney function and chronic kidney damage; (ii) Accurate information regarding renal protein loss, an important and early marker of kidney disease, is lacking; (iii) Cardiovascular risk factors for CKD, such as obesity, hypertension and diabetes, are often not searched for. Likewise non-classic potential risk factors, such as endemic infectious diseases, socioeconomic status and lifestyle have not been consistently recorded; (iv) Information to interrogate linked interaction over time between risk factors and development of CKD is unavailable. With this project, situated in a region representative of semi-rural SSA, we aim to fill this knowledge gap and (i) establish guideline conform prevalence data of CKD and its major cardiovascular risk factors, as well as (ii) prospectively define the incidence of cardiovascular- and non-classic risk factors of CKD. The data from (i) and (ii) is used to develop predictive models. A prospective cohort of 1200 individuals in a primary care facility will serve as study population. The population is representing a society in transition from rural to more urban lifestyle. In the pilot study, participants will be followed for one years and undergo the clinical and biomedical testing required to capture CKD and its classic and non-classic risk factors over time.

Conditions

Sponsors & Collaborators

  • University Hospital, Basel, Switzerland

    collaborator OTHER
  • Ifakara Health Institute

    collaborator OTHER
  • Swiss Tropical & Public Health Institute

    lead OTHER

Principal Investigators

  • Michael Mayr, MD · University Hospital, Basel, Switzerland

  • Daniel H Paris, Prof · Swiss Tropical & Public Health Institute

  • Nikolai C Hodel, MSc · Swiss Tropical & Public Health Institute

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-06-21
Primary Completion
2026-12-31
Completion
2026-12-31

Countries

  • Tanzania

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05881447 on ClinicalTrials.gov